CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Report for D009103: Multiple Sclerosis NIH

(Synonyms: Multiple Scl, Multiple Scler, Multiple Sclerosis)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug293 Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2) Wiki 0.71
drug699 Rifampin Wiki 0.71
drug82 Azithromycin Wiki 0.15

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D009471 Neuromyelitis Optica NIH 0.71
D012598 Scoliosi NIH 0.50
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.11

There are 2 clinical trials

Clinical Trials

1 Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis

Multiple sclerosis (MS) is an inflammatory, demyelinating disease which affects the central nervous system (CNS). The etiology of MS is unknown, although the immune system appears to play a role. Many different infectious agents have been proposed as potential causes for MS, including Epstein-Barr virus, human herpesvirus 6, and coronaviruses. Recently Dr. Sriram at Vanderbilt University has found evidence for active Chlamydia pneumonia infection in the CNS of MS patients. These findings have been replicated in part by other laboratories. The purpose of the current study is to test whether antibiotic treatment aimed at eradicating Chlamydia infection will reduce the disease activity in MS. The primary outcome measure will be reduction in new enhancing MS lesions on brain MRI. Forty patients will be entered into the trial. To be eligible, patients must have evidence of chlamydia infection in their spinal fluid and enhancing lesions on their pre-randomization MRI scans. Patients who meet these criteria will be randomized to either placebo or antibiotic therapy, and followed for 6 months on treatment.

NCT00043264 Multiple Sclerosis Drug: Rifampin Drug: Azithromycin
MeSH:Pneumonia Multiple Sclerosis Sclerosis

2 Cohort Study Evaluating the Epidemiological Characteristics of Coronavirus Infection (SARS-CoV-2) in Patients With MS or NMO

The purpose of this study is to collect French medical data for patients with Multiple Sclerosis (MS) or NeuroMyelitis Optica (NMO) spectrum disorder who are diagnosed or strongly suspected of being infected with Covid19. The objective of this study is to provide scientific information regarding the possible risk factors in these patients, as a large part of them receive immunomodulatory or immunosuppressive treatments. The main objective of this study is thus to determine the epidemiological (eg, age, form of disease, disability) and pharmacological (related to immunomodulatory or immunosuppressive treatments) factors favoring the occurrence of a severe form of Covid-19 in MS and NMO patients.

NCT04355611 Multiple Sclerosis NMO Spectrum Disorder COVID-19 Other: Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2)
MeSH:Multiple Sclerosis Neuromyelitis Optica

Primary Outcomes

Description: The main outcome measure is a clinical severity score on a 7-point severity scale at Nadir (in medicine, the most severe point in the progression of symptoms of a pathology). Nadir scale from 1 : Not hospitalized, no limitation of activities to 7 :Death

Measure: Clinical severity

Time: 6 months

Secondary Outcomes

Description: EDSS is the Expanded Disability Severity Scale, a measure of neurological disability in patients with MS or NMO. EDSS Scale from 0: normal neurological examination to 10: MS-related Death

Measure: EDSS (Expanded Disability Status Scale)

Time: 6 months

HPO Nodes